MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'American Journal of Hematology' source. Sun, 21 Mar 2010 15:13:00 +0100 http://www.medworm.com/index.php?rid=3384275&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21681 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3384275 Sat, 20 Mar 2010 00:00:00 +0100 3384275 http://www.medworm.com/index.php?rid=3380595&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21654 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3380595 Fri, 19 Mar 2010 00:00:00 +0100 3380595 http://www.medworm.com/index.php?rid=3364652&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21682 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3364652 Mon, 15 Mar 2010 00:00:00 +0100 3364652 http://www.medworm.com/index.php?rid=3360863&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21677 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3360863 Sat, 13 Mar 2010 00:00:00 +0100 3360863 http://www.medworm.com/index.php?rid=3333033&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21690 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3333033 Fri, 05 Mar 2010 00:00:00 +0100 3333033 http://www.medworm.com/index.php?rid=3324544&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21666 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3324544 Wed, 03 Mar 2010 00:00:00 +0100 3324544 http://www.medworm.com/index.php?rid=3285475&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21646 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3285475 Fri, 19 Feb 2010 00:00:00 +0100 3285475 http://www.medworm.com/index.php?rid=3277540&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21619 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3277540 Wed, 17 Feb 2010 00:00:00 +0100 3277540 http://www.medworm.com/index.php?rid=3256550&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21650 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3256550 Tue, 09 Feb 2010 00:00:00 +0100 3256550 http://www.medworm.com/index.php?rid=3252258&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21631 Chromosome 8p11.2 translocations result in diverse oncogenic fusion genes involving FGFR1 or MYST3. Among 24,262 unique patient cytogenetic studies performed at the Mayo Clinic, 8p11.2 translocations were identified in 14 cases ([sim]0.06%). FISH analysis was performed in 13 patients (12 had myeloid neoplasms) and revealed abnormalities of MYST3 (n = 4) or FGFR1 (n = 4) in eight patients. MYST3 abnormalities were associated with acute myeloid leukemia (AML), M4 in three and M6 in one. Three of the four FGFR1-rearranged cases were associated with myeloproliferative neoplasms but none, including the two with sole 8p11.2, displayed the typical phenotype for stem cell leukemia/lymphoma (SCLL) and only one had eosinophilia; the fourth case had AML-M4. FISH did not reveal FGFR1 involvement in th... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3252258 Tue, 09 Feb 2010 00:00:00 +0100 3252258 http://www.medworm.com/index.php?rid=3384276&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21680 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3384276 Mon, 08 Feb 2010 00:00:00 +0100 3384276 http://www.medworm.com/index.php?rid=3367770&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21668 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3367770 Mon, 08 Feb 2010 00:00:00 +0100 3367770 http://www.medworm.com/index.php?rid=3367769&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21670 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3367769 Mon, 08 Feb 2010 00:00:00 +0100 3367769 http://www.medworm.com/index.php?rid=3367768&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21672 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3367768 Mon, 08 Feb 2010 00:00:00 +0100 3367768 http://www.medworm.com/index.php?rid=3360865&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21669 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3360865 Mon, 08 Feb 2010 00:00:00 +0100 3360865 http://www.medworm.com/index.php?rid=3360864&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21674 This article summarizes available laboratory testing of aspirin response with focus on technical issues, limitations, and current opinion on the utility of routine patient testing. Am. J. Hematol., 2010. © 2010 Wiley-Liss, Inc. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3360864 Mon, 08 Feb 2010 00:00:00 +0100 3360864 http://www.medworm.com/index.php?rid=3237455&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21649 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3237455 Thu, 04 Feb 2010 00:00:00 +0100 3237455 http://www.medworm.com/index.php?rid=3233256&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21628 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3233256 Wed, 03 Feb 2010 00:00:00 +0100 3233256 http://www.medworm.com/index.php?rid=3252260&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21647 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3252260 Fri, 29 Jan 2010 00:00:00 +0100 3252260 http://www.medworm.com/index.php?rid=3360867&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21663 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3360867 Wed, 27 Jan 2010 00:00:00 +0100 3360867 http://www.medworm.com/index.php?rid=3360866&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21664 Everolimus is an oral antineoplastic agent that targets the raptor mammalian target of rapamycin (mTORC1). The phosphatidylinositol 3-kinase/mTOR signal transduction pathway has been demonstrated to be activated in tumor samples from patients with Hodgkin lymphoma (HL). The goal of this trial was to learn the antitumor activity and toxicity of everolimus in patients with relapsed/refractory HL. Patients were eligible if they had measurable disease, a platelet count >75,000, and an absolute neutrophil count >1,000. Patients received everolimus 10 mg PO daily. Dose reductions were allowed. Response was assessed after two and six cycles and then every three cycles until progression. Patients could remain on drug until progression or toxicity. Nineteen patients were enrolled. Median age was 37... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3360866 Wed, 27 Jan 2010 00:00:00 +0100 3360866 http://www.medworm.com/index.php?rid=3333038&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21662 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3333038 Wed, 27 Jan 2010 00:00:00 +0100 3333038 http://www.medworm.com/index.php?rid=3324545&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21661 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3324545 Tue, 26 Jan 2010 00:00:00 +0100 3324545 http://www.medworm.com/index.php?rid=3333041&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21648 The chemotherapy dose-intensity in two adapted German BFM paediatric protocols (BFM 90 and NHL 86) was compared in contemporaneously treated adults (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3333041 Wed, 20 Jan 2010 00:00:00 +0100 3333041 http://www.medworm.com/index.php?rid=3333040&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21657 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3333040 Wed, 20 Jan 2010 00:00:00 +0100 3333040 http://www.medworm.com/index.php?rid=3333039&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21659 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3333039 Wed, 20 Jan 2010 00:00:00 +0100 3333039 http://www.medworm.com/index.php?rid=3333034&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21656 On June 30, 2009, the United States Food and Drug Administration (FDA) approved ferumoxytol (FerahemeTM injection, AMAG Pharmaceuticals), an iron-containing product for intravenous (IV) administration, for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). The safety and efficacy of ferumoxytol were assessed in three randomized, open-label, controlled clinical trials. Two trials evaluated patients with nondialysis dependent CKD and a third trial assessed patients undergoing hemodialysis. Randomization was either to ferumoxytol or oral iron. Ferumoxytol was administered as two 510 mg IV injections, separated by 3-8 days. Oral iron, Ferro-Sequels®, was administered at a dose of 100 mg twice daily for 21 days. In all three clinical trials, ferumoxyto... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3333034 Wed, 20 Jan 2010 00:00:00 +0100 3333034 http://www.medworm.com/index.php?rid=3324551&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21655 Combination immunochemotherapy is the most common approach for initial therapy of patients with advanced-stage follicular lymphoma, but no consensus exists as to the optimal selection or sequence of available regimens. We undertook this decision analysis to systematically evaluate the parameters affecting the choice of early therapy in patients with this disease. We designed a Markov model incorporating the three most commonly utilized regimens (RCVP, RCHOP, and RFlu) in combinations of first- and second-line therapies, with the endpoint of number of quality-adjusted life years (QALYs) until disease progression. Data sources included Phase II and Phase III trials and literature estimates of long-term toxicities and health state utilities. Meta-analytic methods were used to derive the value... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3324551 Wed, 20 Jan 2010 00:00:00 +0100 3324551 http://www.medworm.com/index.php?rid=3324549&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21652 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3324549 Wed, 20 Jan 2010 00:00:00 +0100 3324549 http://www.medworm.com/index.php?rid=3324548&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21653 Malaria and HIV-1 are coendemic in many developing countries, with anemia being the most common pediatric hematological manifestation of each disease. Anemia is also one of the primary causes of mortality in children monoinfected with either malaria or HIV-1. Although our previous results showed HIV-1(+) children with acute Plasmodium falciparum malaria [Pf(+)] have more profound anemia, potential causes of severe anemia in coinfected children remain unknown. As such, children with P. falciparum malaria (aged 3-36 months, n = 542) from a holoendemic malaria transmission area of western Kenya were stratified into three groups: HIV-1 negative [HIV-1(-)/Pf(+)]; HIV-1 exposed [HIV-1(exp)/Pf(+)]; and HIV-1 infected [HIV-1(+)/Pf(+)]. Comprehensive clinical, parasitological, and hematological mea... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3324548 Wed, 20 Jan 2010 00:00:00 +0100 3324548 http://www.medworm.com/index.php?rid=3324547&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21658 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3324547 Wed, 20 Jan 2010 00:00:00 +0100 3324547 http://www.medworm.com/index.php?rid=3324546&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21660 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3324546 Wed, 20 Jan 2010 00:00:00 +0100 3324546 http://www.medworm.com/index.php?rid=3324550&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21642 Variability in the ability of the malaria parasite Plasmodium falciparum to invade human erythrocytes is postulated to be an important determinant of disease severity. Both the parasite multiplication rate and erythrocyte selectivity are important parameters that underlie such variable invasion. We have established a flow cytometry-based method for simultaneously calculating both the parasitemia and the number of multiply-infected erythrocytes. Staining with the DNA-specific dye SYBR Green I allows quantitation of parasite invasion at the ring stage of parasite development. We discuss in vitro and in vivo applications and limitations of this method in relation to the study of parasite invasion. Am. J. Hematol., 2010. © 2010 Wiley-Liss, Inc. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3324550 Wed, 13 Jan 2010 00:00:00 +0100 3324550 http://www.medworm.com/index.php?rid=3285478&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21643 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3285478 Wed, 13 Jan 2010 00:00:00 +0100 3285478 http://www.medworm.com/index.php?rid=3285477&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21644 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3285477 Wed, 13 Jan 2010 00:00:00 +0100 3285477 http://www.medworm.com/index.php?rid=3285476&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21645 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3285476 Wed, 13 Jan 2010 00:00:00 +0100 3285476 http://www.medworm.com/index.php?rid=3165328&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21612 No Abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3165328 Wed, 13 Jan 2010 00:00:00 +0100 3165328 http://www.medworm.com/index.php?rid=3154670&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21606 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3154670 Sat, 09 Jan 2010 00:00:00 +0100 3154670 http://www.medworm.com/index.php?rid=3324552&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21634 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3324552 Fri, 08 Jan 2010 00:00:00 +0100 3324552 http://www.medworm.com/index.php?rid=3285480&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21635 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3285480 Fri, 08 Jan 2010 00:00:00 +0100 3285480 http://www.medworm.com/index.php?rid=3285479&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21638 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3285479 Fri, 08 Jan 2010 00:00:00 +0100 3285479 http://www.medworm.com/index.php?rid=3277541&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21641 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3277541 Fri, 08 Jan 2010 00:00:00 +0100 3277541 http://www.medworm.com/index.php?rid=3252261&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21639 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3252261 Fri, 08 Jan 2010 00:00:00 +0100 3252261 http://www.medworm.com/index.php?rid=3237457&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21636 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3237457 Fri, 08 Jan 2010 00:00:00 +0100 3237457 http://www.medworm.com/index.php?rid=3237456&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21637 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3237456 Fri, 08 Jan 2010 00:00:00 +0100 3237456 http://www.medworm.com/index.php?rid=3147391&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21601 In this study, we performed detailed sequence analysis of the RPS19 gene in 239 patients with DBA and 110 of their relatives. We found that 6.2% of the patients with DBA carried allelic variations upstream of ATG: 3.3% with c.-1 + 26G>T; 2.5% with c.-147_-146insGCCA; and 0.4% with c.-174G>A. Interestingly, the c.-147_-146insGCCA, which has been found in a black American and French Caribbean control population, was not found in 500 Caucasian control chromosomes we studied. However, it was found in association with the same haplotype distribution of four intronic polymorphisms in our patients with DBA. Although a polymorphism, the frequency of this variant in the patients with DBA and its association with the same haplotype raises the possibility that this polymorphism and the other genetic ... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3147391 Thu, 07 Jan 2010 00:00:00 +0100 3147391 http://www.medworm.com/index.php?rid=3277543&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21630 In this study, we retrospectively investigated the clinical outcomes of RIC with fludarabine (Flu; 180 mg/m2), intravenous busulfan (BU; 6.4 mg/kg) or oral BU (8 mg/kg), and low-dose total body irradiation (TBI; 4 Gy) (Flu-BU2-TBI) in 66 patients (median age: 54.5 years) with various hematological malignancies. Thirty-eight patients (58%) were high-risk patients (median age: 56 years). The overall survival rate at 2 years of the high-risk patients was 64.5%, which was comparable to the survival rate of 70.9% in standard-risk patients (P = 0.68). The relapse rates at 2 years in the standard-risk and high-risk patients were 16 and 28%, respectively, and day 100 treatment-related mortality rates were 0 and 6%, respectively. The Flu-BU2-TBI regimen for high-risk patients showed therapeutic eff... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3277543 Wed, 06 Jan 2010 00:00:00 +0100 3277543 http://www.medworm.com/index.php?rid=3277542&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21633 In multiple myeloma (MM), allogeneic stem cell transplantation (alloHCT) carries a lower relapse risk than autologous transplantation but a greater transplant-related mortality. Nonmyeloablative conditioning for allogeneic transplantation (NST) reduces transplant-related toxicity. Results are encouraging when used during first remission in low-risk patients, but less-so in relapsed or refractory disease. This is a single-center retrospective analysis of 20 previously treated MM patients who underwent NST from matched-related or matched-unrelated donors from 2000-2006. Median age was 52.7 years (37.2-68.0). Twenty-five percent had advanced or high-risk disease. Eleven still had active disease prior to NST. Conditioning was total body irradiation 200 cGy on a single fraction on day -5, follo... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3277542 Wed, 06 Jan 2010 00:00:00 +0100 3277542 http://www.medworm.com/index.php?rid=3237458&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21632 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3237458 Wed, 06 Jan 2010 00:00:00 +0100 3237458 http://www.medworm.com/index.php?rid=3144007&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21603 Systemic light-chain (AL) amyloidosis may be associated with acquired factor X (FX) deficiency and optimal management of this coagulopathy is unknown. We reviewed our experience with 60 patients with isolated FX deficiency ([le]50%) due to AL amyloidosis that underwent an invasive procedure between 1975 and 2007. They were classified as having severe ( (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3144007 Wed, 06 Jan 2010 00:00:00 +0100 3144007 http://www.medworm.com/index.php?rid=3277546&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21613 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3277546 Thu, 31 Dec 2009 00:00:00 +0100 3277546 http://www.medworm.com/index.php?rid=3237459&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21629 (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3237459 Thu, 31 Dec 2009 00:00:00 +0100 3237459 http://www.medworm.com/index.php?rid=3116905&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21592 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3116905 Thu, 24 Dec 2009 00:00:00 +0100 3116905 http://www.medworm.com/index.php?rid=3277544&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21627 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3277544 Wed, 23 Dec 2009 00:00:00 +0100 3277544 http://www.medworm.com/index.php?rid=3252259&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21626 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3252259 Wed, 23 Dec 2009 00:00:00 +0100 3252259 http://www.medworm.com/index.php?rid=3112857&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21584 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3112857 Wed, 23 Dec 2009 00:00:00 +0100 3112857 http://www.medworm.com/index.php?rid=3333037&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21622 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3333037 Tue, 22 Dec 2009 00:00:00 +0100 3333037 http://www.medworm.com/index.php?rid=3333036&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21623 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3333036 Tue, 22 Dec 2009 00:00:00 +0100 3333036 http://www.medworm.com/index.php?rid=3333035&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21624 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3333035 Tue, 22 Dec 2009 00:00:00 +0100 3333035 http://www.medworm.com/index.php?rid=3277545&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21617 The objective of this study is to systematically review methods for detecting Factor V Leiden or prothrombin G20210A. English-language literature from MEDLINE®, EMBASE®, The Cochrane Library, the Cumulative Index to Nursing and Allied Health Literature, PsycInfo©, 2000-December 2008. Studies assessed methods for detection of these mutations in at least 10 human blood samples and reported concordance, discordance, or reproducibility. Two investigators abstracted data on the sample selection criteria, test operators, DNA extraction, experimental test, reference standard, commercial instruments, concordance rates, explanation of any discordance, and whether discordance resolved after repetition. We assessed strength of the evidence using the GRADE criteria. We reviewed 7,777 titles and inc... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3277545 Tue, 22 Dec 2009 00:00:00 +0100 3277545 http://www.medworm.com/index.php?rid=3237462&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21616 Reports of the incidence of ITP are few and their methodology is variable. Accurate estimates of the incidence of immune thrombocytopenic purpura (ITP) are important to understand the medical and public health impact of the disease. To critically review all published reports on the incidence of ITP in children and adults, all articles identified on the Medline database (searched January 1, 1966-August 7, 2009) that reported data on the incidence of ITP were retrieved. Articles which directly estimated the incidence of ITP were selected for review. Eight articles reported the incidence of acute ITP in children. After review, four were determined to have the strongest estimates, based on the method of patient identification and study design. The lowest incidence estimate in these four studie... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3237462 Tue, 22 Dec 2009 00:00:00 +0100 3237462 http://www.medworm.com/index.php?rid=3237461&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21618 This study suggests that ALC at diagnosis is a prognostic factor for OS in MDS, and argues in favor of further studies to assess the role of host immunity in MDS clinical outcomes. Am. J. Hematol. 2010. © 2009 Wiley-Liss, Inc. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3237461 Tue, 22 Dec 2009 00:00:00 +0100 3237461 http://www.medworm.com/index.php?rid=3237460&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21621 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3237460 Tue, 22 Dec 2009 00:00:00 +0100 3237460 http://www.medworm.com/index.php?rid=3233257&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21620 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3233257 Tue, 22 Dec 2009 00:00:00 +0100 3233257 http://www.medworm.com/index.php?rid=3237463&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21615 Dasatinib 70 mg twice daily is indicated for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) intolerant or resistant to imatinib. In patients with chronic-phase chronic myelogenous leukemia, once-daily dosing has similar efficacy with improved safety, compared with twice-daily dosing. A phase 3 study (n = 611) assessed the efficacy and safety of dasatinib 140 mg once daily versus 70 mg twice-daily in patients with advanced phase chronic myelogenous leukemia or Ph+ ALL resistant or intolerant to imatinib. Here, results from the Ph+ ALL subset (n = 84) with a 2-year follow-up are reported. Patients were randomly assigned to receive dasatinib either 140 mg once daily (n = 40) or 70 mg twice daily (n = 44). The rate of confirmed major hematologic response with once-dail... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3237463 Tue, 15 Dec 2009 00:00:00 +0100 3237463 http://www.medworm.com/index.php?rid=3144010&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21614 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3144010 Tue, 15 Dec 2009 00:00:00 +0100 3144010 http://www.medworm.com/index.php?rid=3165329&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21611 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3165329 Thu, 10 Dec 2009 00:00:00 +0100 3165329 http://www.medworm.com/index.php?rid=3237466&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21607 Maintaining a balance between bleeding and clotting has always been a challenge in treating coagulation disorders. A perturbation in that balance can be associated with substantial morbidity and mortality. As a result, anticoagulant monitoring is extremely important, and inappropriate testing may lead to complications. There are now a variety of new anticoagulant drugs in clinical use including several direct thrombin inhibitors (DTIs), such as argatroban, bivalirudin, and hirudin, as well as a Factor Xa inhibitor, fondaparinux. There are pitfalls associated with some of the currently used laboratory monitoring tests, and newer alternative laboratory monitoring tests have been investigated (Walenga and Hoppensteadt, Semin Thromb Hemost 2004;30:683-695). In addition, laboratory testing can ... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3237466 Fri, 04 Dec 2009 00:00:00 +0100 3237466 http://www.medworm.com/index.php?rid=3237464&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21608 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3237464 Fri, 04 Dec 2009 00:00:00 +0100 3237464 http://www.medworm.com/index.php?rid=3233258&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21609 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3233258 Fri, 04 Dec 2009 00:00:00 +0100 3233258 http://www.medworm.com/index.php?rid=3049894&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21565 The objectives of our study were to examine the variation between hospitals in their use of corticosteroids for ACS, describe characteristics associated with corticosteroids, and investigate the association between corticosteroids, length of stay, and readmission. We performed a retrospective examination of 5,247 hospitalizations for ACS between January 1, 2004, and June 30, 2008, at 32 hospitals in the Pediatric Health Information System database. We used multivariate regression to examine the variability in the use of corticosteroids adjusting for hospital case mix, identify factors associated with corticosteroid use, and evaluate the association of corticosteroids with length of stay and 3-day readmission rates controlling for propensity score. Corticosteroid use varied greatly by hospi... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3049894 Thu, 03 Dec 2009 00:00:00 +0100 3049894 http://www.medworm.com/index.php?rid=3237465&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21605 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3237465 Tue, 01 Dec 2009 00:00:00 +0100 3237465 http://www.medworm.com/index.php?rid=3154671&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21604 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3154671 Tue, 01 Dec 2009 00:00:00 +0100 3154671 http://www.medworm.com/index.php?rid=3144013&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21599 The objectives of this review are to provide readers with an overview of the process of banking RBC that may have an impact on its quality, the reported clinical impact of storage lesions, the consequences of transfusing new RBC units only to the nation's blood supply and potential solutions that may improve the feasibility of blood banks to issue new blood units only. Am. J. Hematol., 2010. © 2009 Wiley-Liss, Inc. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3144013 Wed, 18 Nov 2009 00:00:00 +0100 3144013 http://www.medworm.com/index.php?rid=3144012&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21594 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3144012 Wed, 18 Nov 2009 00:00:00 +0100 3144012 http://www.medworm.com/index.php?rid=3144011&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21596 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3144011 Wed, 18 Nov 2009 00:00:00 +0100 3144011 http://www.medworm.com/index.php?rid=3144009&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21597 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3144009 Wed, 18 Nov 2009 00:00:00 +0100 3144009 http://www.medworm.com/index.php?rid=3144008&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21598 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3144008 Wed, 18 Nov 2009 00:00:00 +0100 3144008 http://www.medworm.com/index.php?rid=3147392&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21591 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3147392 Mon, 16 Nov 2009 00:00:00 +0100 3147392 http://www.medworm.com/index.php?rid=3144014&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21593 There is evidence that leukocytosis is associated with an increased risk of first thrombosis in patients with polycythemia vera (PV) and essential thrombocythemia (ET). Whether it is a risk factor for recurrent thrombosis too is currently unknown. In the frame of a multicenter retrospective cohort study, we recruited 253 patients with PV (n = 133) or ET (n = 120), who were selected on the basis of a first arterial (70%) or venous major thrombosis (27.6%) or both (2.4%), and who were not receiving cytoreduction at the time of thrombosis. The probability of recurrent thrombosis associated with the leukocyte count recorded at the time of the first thrombosis was estimated by a receiver operating characteristic analysis and a multivariable Cox proportional hazards regression model. Thrombosis ... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3144014 Mon, 16 Nov 2009 00:00:00 +0100 3144014 http://www.medworm.com/index.php?rid=3144015&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21588 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3144015 Thu, 12 Nov 2009 00:00:00 +0100 3144015 http://www.medworm.com/index.php?rid=3112859&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21587 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3112859 Thu, 12 Nov 2009 00:00:00 +0100 3112859 http://www.medworm.com/index.php?rid=3112858&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21589 No abstract. Am. J. Hematol., 2009. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3112858 Thu, 12 Nov 2009 00:00:00 +0100 3112858 http://www.medworm.com/index.php?rid=2975185&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21550 This article provides an overview of the process and describes 12 body system categories and the most prevalent or severe complications within these categories. A detailed Appendix provides standardized definitions for all complications identified within each system. This report proposes use of these definitions for studies of SCD complications, so future studies can be comparably robust and treatment efficacy measured. Use of these definitions will support greater accuracy in genotype-phenotype studies, thereby achieving a better understanding of SCD pathophysiology. This should nevertheless be viewed as a dynamic rather than final document; phenotype descriptions should be reevaluated and revised periodically to provide the most current standard definitions as etiologic factors are bette... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2975185 Tue, 10 Nov 2009 00:00:00 +0100 2975185 http://www.medworm.com/index.php?rid=2968875&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21575 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2968875 Sat, 07 Nov 2009 00:00:00 +0100 2968875 http://www.medworm.com/index.php?rid=2965009&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21567 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2965009 Fri, 06 Nov 2009 00:00:00 +0100 2965009 http://www.medworm.com/index.php?rid=2956471&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21559 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2956471 Wed, 04 Nov 2009 00:00:00 +0100 2956471 http://www.medworm.com/index.php?rid=3112860&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21581 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3112860 Thu, 29 Oct 2009 00:00:00 +0100 3112860 http://www.medworm.com/index.php?rid=2936488&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21563 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2936488 Thu, 29 Oct 2009 00:00:00 +0100 2936488 http://www.medworm.com/index.php?rid=2932571&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21551 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2932571 Wed, 28 Oct 2009 00:00:00 +0100 2932571 http://www.medworm.com/index.php?rid=3112861&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21573 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3112861 Fri, 23 Oct 2009 00:00:00 +0100 3112861 http://www.medworm.com/index.php?rid=2910235&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21549 Follicular lymphoma (FL) frequently transforms into the more aggressive diffuse large B cell lymphoma (DLBCL-tr), but no protein biomarkers have been identified for predictive or early diagnosis. Gene expression analyses have identified genes changing on transformation but have failed to be reproducible in different studies, reflecting the heterogeneity within the tumor tissue and between tumor samples. Gene expression analyses on Affymetrix Human Genome U133 Plus 2.0 arrays were performed, using flow cytometry sorted tumor cells derived from FL and transformed DLBCL. To identify molecular targets associated with the transformation, subsequent immunohistochemistry (IHC) analyses of the corresponding proteins were performed. Using highly purified cells, this study identified 163 genes, whic... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2910235 Tue, 20 Oct 2009 23:00:00 +0100 2910235 http://www.medworm.com/index.php?rid=3049895&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21564 We studied 160 Hepatitis C virus (HCV)-positive patients with NHL (59 indolent NHL, 101 aggressive). Median age was 67 years. HCV-RNA was present in 146. HBsAg was positive in seven patients. At diagnosis, ALT value was above UNL in 67 patients. One hundred and twenty patients received an anthracycline-based therapy, alkylators, 28 received chemotherapy plus rituximab. Cytotoxic drugs dose was reduced in 63 patients. Among 93 patients with normal ALT at presentation, 16 patients developed WHO grade II-III liver toxicity. Among 67 patients with abnormal ALT, eight patients had a 3.5 times elevation during treatment. Among 28 patients treated with rituximab and chemotherapy, five patients (18%) developed liver toxicity. Thirty four patients (21%) did not complete treatment (eight for liver t... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3049895 Wed, 14 Oct 2009 00:00:00 +0100 3049895 http://www.medworm.com/index.php?rid=3049896&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21562 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3049896 Fri, 09 Oct 2009 00:00:00 +0100 3049896 http://www.medworm.com/index.php?rid=2968876&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21560 We report the results of a phase II trial of the immunotherapeutic, APC8020 (MylovengeTM), given after ASCT for MM. We compared the results with that of other patients with MM who underwent ASCT at Mayo Clinic during the same time period. Twenty-seven patients were enrolled on the trial between July, 1998 and June, 2001, and the outcomes were compared to that of 124 consecutive patients transplanted during the same period, but not enrolled on the trial. The median (range) follow-up for patients still alive from the vaccine trial is 6.5 (2.9-8 years), and 7.1 (6-8 years) in the control group. The median age was 57.4 range (36.1-71.3) in the DB group and 56.4 (range, 30-69) in the trial group. Known prognostic factors including PCLI, B2M, and CRP were comparable between the groups. The media... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2968876 Fri, 09 Oct 2009 00:00:00 +0100 2968876 http://www.medworm.com/index.php?rid=2956472&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21561 Cytoreductive therapy in systemic mastocytosis (SM) includes several drugs whose individual merit has not been well characterized. We retrospectively studied 108 Mayo Clinic patients who met the 2008 WHO diagnostic criteria for SM and received at least one cytoreductive drug. The numbers of patients who were evaluable for response to treatment with interferon-alpha with or without prednisone (IFN-[alpha]), hydroxyurea (HU), imatinib mesylate (IM) or 2-chlorodeoxyadenosine (2-CdA) were 40, 26, 22, and 22, respectively. The corresponding overall (major) response rates, according to recently published consensus criteria, were 53% (18%), 19% (0%), 18% (9%), and 55% (37%). The respective overall response rates in indolent SM, aggressive SM and SM associated with another clonal hematological non... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2956472 Fri, 09 Oct 2009 00:00:00 +0100 2956472 http://www.medworm.com/index.php?rid=3049897&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21558 This study examines how differential expression of NF[kappa]B/p65 (RelA), KLF2, and other transcription factors may act as switches in inflammation signaling leading to observed differences between non-SCA (NS) African Americans and African Americans with SCA who are either at risk (AR) or not at risk (NAR) of childhood stroke based on occurrence of Circle of Willis disease. Clover/Transfac analysis was used to identify overrepresented transcription factor binding motifs on genes associated with inflammation. Transcription factor binding motifs for the NF[kappa]B family and RFX1 were overrepresented on inflammation signaling gene set analysis. Variations in protein expression were determined by flow cytometry of blood outgrowth endothelial cells (BOECs) from NS, AR, and NAR donors and West... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=3049897 Thu, 08 Oct 2009 00:00:00 +0100 3049897 http://www.medworm.com/index.php?rid=2968878&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21555 In this study, the subsequent clinical outcome was overviewed in 292 patients with leukemia/myelodysplastic syndrome who received allo-HCT. Among them, 93 (32%) showed relapse/progression. Cohort 1 was chosen to receive no interventions with curative intent (n = 25). Cohort 2 received reinduction chemotherapy and/or donor lymphocyte infusion (n = 48), and Cohort 3 underwent a second allo-HCT (n = 20). Sixty-three patients received reinduction chemotherapy, and 27 (43%) achieved subsequent complete remission (CR). The incidence of nonrelapse mortality (NRM) was similar among the three cohorts (4, 15, and 5%). The 1-year overall survival (OS) after relapse was significantly better in patients with a second HCT (58%) than in others (14%, Cohorts 1 and 2; P (Source: American Journal of Hematol... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2968878 Thu, 08 Oct 2009 00:00:00 +0100 2968878 http://www.medworm.com/index.php?rid=2968877&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21556 Drug metabolizing genes are involved in the detoxification of chemical carcinogens. Polymorphisms in drug-metabolizing genes affect the risk of some forms of cancer. We analyzed six polymorphisms to evaluate their association with risk for non-Hodgkin lymphoma (NHL), and to examine whether smoking modifies these associations in population-based study in Korea (713 cases and 1,700 controls). The GSTP1 rs1695 AG and the combined AG/GG genotypes were associated with decreased risk of NHL (odds ratio (OR)AG = 0.67, 95% confidence interval (CI) = 0.55-0.82; ORAG/GG = 0.66, 95% CI = 0.54-0.80) and DLBCL (ORAG = 0.63, 95% CI = 0.49-0.82; ORAG/GG = 0.64, 95% CI = 0.50-0.82). For T-cell lymphoma, only the combined AG/GG genotype was associated with decreased risk (ORAG/GG = 0.65, 95% CI = 0.44-0.96... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2968877 Thu, 08 Oct 2009 00:00:00 +0100 2968877 http://www.medworm.com/index.php?rid=2965010&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21554 No published survey has specifically addressed the beliefs, knowledge, and usage of complementary and alternative medicine (CAM) in long-term (5-20 years) lymphoma survivors alone. In this pilot project, 95 subjects were randomly selected from a population of 2,475 long-term lymphoma survivors and mailed a questionnaire. The median time from lymphoma diagnosis to completion of the questionnaire was 11 years (range 6-20). Overall, 68% (95% CI: 54-80%) of the long-term lymphoma survivors reported that they have used CAM, a rate higher than the estimated usage rate reported for the general population The most commonly used modalities were chiropractic (39%, 95% CI: 27-53%) and massage therapy (21%, 95% CI: 12-34%). Less than 10% used meditation (5%, 95% CI: 1-15%) and relaxation (7%, 95% CI: ... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2965010 Thu, 08 Oct 2009 00:00:00 +0100 2965010 http://www.medworm.com/index.php?rid=2956473&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21557 In this study, we conducted a retrospective analysis to identify the clinical features and outcomes of relapsed or refractory MZL. From 1995 to 2008, a total of 92 patients with relapsed MZL were retrospectively analyzed. The median age of our subjects was 53.5 years (range: 23-82 years). The most common primary sites of involvement were the orbit and ocular adnexa (28.3%) followed by the lymph node and lymphatic organs (23.9%), and multiple mucosa-associated lymphoid tissue (MALT) sites (13.0%). The median time to relapse from initial diagnosis was 25.5 months. Of the 53 patients with Stage I or II at diagnosis, 42 patients (79.2%) evidenced locoregional recurrence. Among these locoregional relapsed patients, 27 patients achieved CR (54.1%) or PR (18.9%). In addition to the 39 patients in... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2956473 Thu, 08 Oct 2009 00:00:00 +0100 2956473 http://www.medworm.com/index.php?rid=2867183&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21541 We describe a retrospective analysis of iron overload, and its related complications in 31 transfusion-dependent Italian DBA patients whose records included one or more evaluation of liver iron concentration (LIC) by means of noninvasive magnetic liver susceptometry with a superconductive quantum interference device (SQUID). This cohort is also matched with a group of transfusion-dependent [beta]-thalassemia major patients to look for differences. A severe iron overload was observed in 54% patients, especially among those inadequately chelated. The DBA patients displayed a significantly higher LIC than the regularly chelated [beta]-thalassemics. This difference may have been attributable to nonoptimal chelation (late onset, type, dose, prescription, and compliance), or an unknown biologica... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2867183 Tue, 06 Oct 2009 23:00:00 +0100 2867183 http://www.medworm.com/index.php?rid=2864032&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21545 The current salvage therapies for relapsed/refractory acute myeloid leukemia (AML) are unsatisfactory. Over the past 7 years, we have used two salvage regimens: fludarabine, cytarabine, and idarubicin with (FLAG-IM) or without gemtuzumab ozogamicin (GO) (9 mg/m2 on Day 8) (FLAG-I) in relapsed/refractory AML. Three-quarters of patients also received concurrent G-CSF. Seventy-one patients were treated, 23 with FLAG-I and 48 with FLAG-IM. The median duration of follow-up was 30.6 months. The treatment groups were well balanced with median ages of 48 years (range 18-70) and 47 years (range 20-68), unfavorable cytogenetics in 57% and 35%, prior allogeneic stem cell transplant in 43% and 42%, and CR1 duration (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2864032 Mon, 05 Oct 2009 23:00:00 +0100 2864032 http://www.medworm.com/index.php?rid=2856681&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21538 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2856681 Fri, 02 Oct 2009 23:00:00 +0100 2856681 http://www.medworm.com/index.php?rid=2844478&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21534 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2844478 Tue, 29 Sep 2009 23:00:00 +0100 2844478 http://www.medworm.com/index.php?rid=2932572&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21553 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2932572 Tue, 29 Sep 2009 00:00:00 +0100 2932572 http://www.medworm.com/index.php?rid=2840338&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21523 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2840338 Mon, 28 Sep 2009 23:00:00 +0100 2840338 http://www.medworm.com/index.php?rid=2932573&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21552 The combination of cyclophosphamide and granulocyte-colony stimulating factor (G-CSF) has widely been used to mobilize hematopoietic stem cells (HSCs) for autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Recently, however, alternative approaches such as G-CSF alone or etoposide followed by G-CSF have been investigated. We, therefore, retrospectively analyzed the effects of these mobilization methods on collection yield and disease outcome in ASCT for MM. We reviewed 146 MM patients from whom we intended to collect stem cells. For mobilization, 67, 58, and 21 patients received cyclophosphamide and G-CSF, etoposide and G-CSF, and G-CSF alone (including nonmyelosuppressive chemotherapy followed by G-CSF), respectively. Among them, 136 achieved the target number of HSCs (... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2932573 Mon, 28 Sep 2009 00:00:00 +0100 2932573 http://www.medworm.com/index.php?rid=2910238&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21546 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2910238 Tue, 15 Sep 2009 23:00:00 +0100 2910238 http://www.medworm.com/index.php?rid=2910237&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21548 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2910237 Tue, 15 Sep 2009 23:00:00 +0100 2910237 http://www.medworm.com/index.php?rid=2910236&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21547 The management of hematological malignancies during pregnancy is a challenging endeavor, which not only requires technical skills and knowledge by the clinicians but also requires sound clinical judgment and compassion, keeping in mind the patient and family preferences and, ultimately, the wellbeing of the neonate. The incidence of hematological malignancies during pregnancy is rare, ranging from 1 in 1,000 to 1 in 10,000 deliveries, impeding the design and execution of large prospective studies. The purpose of this review is to evaluate the limited existing data and make useful suggestions in the management of acute and chronic leukemias, Hodgkin and non-Hodgkin lymphomas, plasma cell myeloma, and other hematological malignancies, such as myelodysplastic syndromes and hairy cell leukemia... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2910236 Tue, 15 Sep 2009 23:00:00 +0100 2910236 http://www.medworm.com/index.php?rid=2780059&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21515 Although most patients with sickle cell disease (SCD) are hospitalized infrequently and manage painful crises at home, a small subpopulation is frequently admitted to emergency departments and inpatient units. This small group accounts for the majority of health care expenses for patients with SCD. Using inpatient claims data from a large, urban Medicaid MCO for 5 consecutive years, this study sought to describe the course of high inpatient utilization (averaging four or more admissions enrolled per year for at least 1 year) in members with a diagnosis of SCD and a history of hospitalizations for vaso-occlusive crisis. High utilizers were compared with the other members with SCD on demographics, medical and psychiatric comorbidity, and use of other health care resources. Members who were h... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2780059 Wed, 09 Sep 2009 23:00:00 +0100 2780059 http://www.medworm.com/index.php?rid=2864033&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21544 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2864033 Tue, 08 Sep 2009 23:00:00 +0100 2864033 http://www.medworm.com/index.php?rid=2764049&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21517 This clinical trial was conducted to determine the safety and efficacy of bortezomib retreatment in patients with multiple myeloma (MM) who had previously responded to bortezomib. Patients with progressive MM who had previously tolerated bortezomib as a single agent or in combination with other drugs, with a minimum of partial response (PR; [ge]50% M-protein reduction) for [ge]4 months, who had not received intervening MM therapy, were retreated with bortezomib (days 1, 4, 8, and 11 of a 21-day cycle) with a starting dose being the dose at which the patient ended the initial treatment. Patients were allowed to receive bortezomib on retreatment in combination with dexamethasone, thalidomide, or doxorubicin. Thirty-two patients received bortezomib retreatment (most with added dexamethasone).... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2764049 Thu, 03 Sep 2009 23:00:00 +0100 2764049 http://www.medworm.com/index.php?rid=2910239&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21543 The concept of prodromal chronic myeloproliferative neoplasms has been endorsed by the WHO classification implicating a stepwise evolution of disease. Histology of the bone marrow (BM) and borderline to mildly expressed clinical features play a pivotal role for diagnosing prefibrotic-early primary myelofibrosis. By lowering the platelet count for essential thrombocythemia and regarding BM morphology, early manifestations are tackled. Pre-polycythemic stages of polycythemia vera with a low hemoglobin level at onset are diagnosed by positive JAK2V617F mutation status, a low erythropoietin value, and characteristic BM features. The revised WHO classification incorporates hematological, morphological, and moleculargenetic parameters to generate a consensus-based working diagnosis. Am. J. Hemat... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2910239 Wed, 02 Sep 2009 23:00:00 +0100 2910239 http://www.medworm.com/index.php?rid=2864035&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21540 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2864035 Wed, 02 Sep 2009 23:00:00 +0100 2864035 http://www.medworm.com/index.php?rid=2864034&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21542 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2864034 Wed, 02 Sep 2009 23:00:00 +0100 2864034 http://www.medworm.com/index.php?rid=2749091&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21510 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2749091 Mon, 31 Aug 2009 23:00:00 +0100 2749091 http://www.medworm.com/index.php?rid=2739199&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21530 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2739199 Thu, 27 Aug 2009 23:00:00 +0100 2739199 http://www.medworm.com/index.php?rid=2910240&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21537 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2910240 Mon, 24 Aug 2009 23:00:00 +0100 2910240 http://www.medworm.com/index.php?rid=2867184&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21539 This study strongly suggests that ribosomal readthrough should be considered a strategy for developing experimental strategies for the treatment of [beta]0-thalassemia caused by stop codon mutations. Am. J. Hematol., 2009. © 2009 Wiley-Liss, Inc. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2867184 Mon, 24 Aug 2009 23:00:00 +0100 2867184 http://www.medworm.com/index.php?rid=2856682&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21536 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2856682 Mon, 24 Aug 2009 23:00:00 +0100 2856682 http://www.medworm.com/index.php?rid=2728233&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21507 Although cardiopulmonary disease is associated with decreased functional capacity among adults with sickle cell disease (SCD), its impact on functional capacity in children with SCD is unknown. We evaluated 6-min walk (6MW) distance in 77 children and young adults with SCD undergoing screening for cardiopulmonary disease. Of 30 subjects who also underwent cardiopulmonary exercise testing, we found evidence for decreased exercise capacity in a significant proportion. Exercise capacity was related to baseline degree of anemia and was significantly lower in subjects with a history of recurrent acute chest syndrome. We found that 6MW distance adjusted for weight and body surface area was shorter in subjects with restrictive lung disease but that only 6MW adjusted for weight remained significan... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2728233 Mon, 24 Aug 2009 23:00:00 +0100 2728233 http://www.medworm.com/index.php?rid=2710526&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21496 This study includes 19patients with post-ET BP diagnosed and followed in a single institution. At BP, 63% of patients had leukocytosis (white blood cell count >10 × 109/L), 74% had anemia (hemoglobin value (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2710526 Tue, 18 Aug 2009 23:00:00 +0100 2710526 http://www.medworm.com/index.php?rid=2856683&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21531 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2856683 Mon, 17 Aug 2009 23:00:00 +0100 2856683 http://www.medworm.com/index.php?rid=2840342&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21532 Combined deficiency of coagulation factor V (FV) and factor VIII (FVIII) (F5F8D) is an inherited bleeding disorder characterized by a reduction in plasma concentrations of FV and FVIII. F5F8D is genetically linked to mutations in either LMAN1 or MCFD2. Here, we investigated the molecular basis of F5F8D in a Japanese patient, and identified a novel missense mutation (p.Trp67Ser, c.200G>C) in the LMAN1, but no mutation in the MCFD2. The amount of LMAN1 in Epstein-Barr virus-immortalized lymphoblasts from the patient was found to be almost the same as that in cells from a normal individual. Interestingly, an anti-MCFD2 antibody did not co-immunoprecipitate the mutant LMAN1 with MCFD2 in lymphoblasts from the patient, suggesting the affinity of MCFD2 for the mutant LMAN1 is weak or abolished b... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2840342 Mon, 17 Aug 2009 23:00:00 +0100 2840342 http://www.medworm.com/index.php?rid=2840341&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21533 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2840341 Mon, 17 Aug 2009 23:00:00 +0100 2840341 http://www.medworm.com/index.php?rid=2840340&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21535 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2840340 Mon, 17 Aug 2009 23:00:00 +0100 2840340 http://www.medworm.com/index.php?rid=2693401&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21497 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2693401 Wed, 12 Aug 2009 23:00:00 +0100 2693401 http://www.medworm.com/index.php?rid=2864036&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21528 To identify patients who developed secondary clonal cytogenetic aberrations (CCA) following therapy for acute promyelocytic leukemia (APL), we retrospectively analyzed cytogenetic results from 123 patients diagnosed with APL between 1995 and 2007, who had ongoing cytogenetic analysis undertaken in our laboratory. During follow-up for APL we identified 12 patients (9.8%) who developed CCA, not detected at diagnosis of APL and unrelated to their original APL karyotype. All patients had received all-trans retinoic acid (ATRA) and chemotherapy and were in complete remission for APL when secondary CCA were identified. The median latency period between diagnosis of APL and emergence of secondary CCA was 27.5 months (range: 2-54 months). To date, four patients with CCA have been diagnosed with th... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2864036 Mon, 10 Aug 2009 23:00:00 +0100 2864036 http://www.medworm.com/index.php?rid=2856685&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21525 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2856685 Mon, 10 Aug 2009 23:00:00 +0100 2856685 http://www.medworm.com/index.php?rid=2856684&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21529 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2856684 Mon, 10 Aug 2009 23:00:00 +0100 2856684 http://www.medworm.com/index.php?rid=2840344&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21526 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2840344 Mon, 10 Aug 2009 23:00:00 +0100 2840344 http://www.medworm.com/index.php?rid=2840343&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21527 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2840343 Mon, 10 Aug 2009 23:00:00 +0100 2840343 http://www.medworm.com/index.php?rid=2840339&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21524 We sought to identify mutations that could explain iron phenotype heterogeneity in adults with previous HFE genotyping to detect C282Y and H63D. HEIRS Study participants genotyped for C282Y and H63D were designated as high transferrin saturation (TS) and/or serum ferritin (SF) (high TS/SF), low TS/SF, or controls. We grouped 191 C282Y homozygotes as high TS/SF, low TS/SF, or controls, and 594 other participants by race/ethnicity as high TS/SF or controls. Using denaturing high-performance liquid chromatography (DHPLC), we screened 20 regions of HFE, SLC40A1, HAMP, HJV, TFR2, and FTL in each participant. DHPLC analyses were successful in 99.3% of 791 participants and detected 117 different mutations. In C282Y homozygotes, 4.0% of high TS/SF participants had SLC40A1 Q248H, HAMP -72C>T, or HA... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2840339 Mon, 10 Aug 2009 23:00:00 +0100 2840339 http://www.medworm.com/index.php?rid=2840345&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21520 In this study, we examined differences in inpatient costs, length of stay, and in-hospital mortality between hospitalizations for patients with and without sickle cell disease (SCD) undergoing high-volume surgical procedures. We used Clinical Classification Software (CCS) codes to identify discharges in the 2002-2005 Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project for patients who had undergone either cholecystectomy or hip replacement. We limited the non-SCD cohort to hospitals where patients with SCD had undergone the same procedure. We compared inpatient outcomes using summary statistics and generalized linear regression analysis to adjust for patient, hospital, and procedural characteristics. Overall, the median age of surgical patients with SCD was more than... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2840345 Sun, 09 Aug 2009 23:00:00 +0100 2840345 http://www.medworm.com/index.php?rid=2802192&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21518 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2802192 Sun, 09 Aug 2009 23:00:00 +0100 2802192 http://www.medworm.com/index.php?rid=2802191&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21519 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2802191 Sun, 09 Aug 2009 23:00:00 +0100 2802191 http://www.medworm.com/index.php?rid=2672809&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21489 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2672809 Wed, 05 Aug 2009 23:00:00 +0100 2672809 http://www.medworm.com/index.php?rid=2659204&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21482 The approved 7-day schedule of subcutaneous azacitidine for myelodysplastic syndrome is associated with injection site reactions and bruising and may be inconvenient because of the need for weekend doses. Although pharmacokinetic data with IV azacitidine suggests equivalence, there are no efficacy data published. Patients with all myelodysplastic syndromes (MDS) FAB subtypes were enrolled and received 75 mg/m2/d of azacitidine by 20-min intravenous infusion for 5 days in every 28 days. Global methylation studies were performed at baseline and prior to Cycle 3. Twenty-five patients were enrolled and 22 were evaluable. Median age was 69.5 years; 9 (41%) patients had lower-risk disease (IPSS Low or Int-1) and 13 (59%) had higher-risk disease (IPSS Int-2 or High). Twenty-seven percent of patie... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2659204 Fri, 31 Jul 2009 23:00:00 +0100 2659204 http://www.medworm.com/index.php?rid=2764050&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21516 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2764050 Wed, 29 Jul 2009 23:00:00 +0100 2764050 http://www.medworm.com/index.php?rid=2764052&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21508 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2764052 Fri, 24 Jul 2009 23:00:00 +0100 2764052 http://www.medworm.com/index.php?rid=2764051&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21512 This study investigated responses to retreatment with rituximab in chronic immune thrombocytopenic purpura (ITP) patients. Treatment with rituximab in chronic ITP patients induces long-lasting responses in [sim]30% of patients but even these patients may relapse. Twenty patients who had achieved a response to rituximab and relapsed were retreated with rituximab (375 mg/m2× 4); this data was analyzed retrospectively. Subsequently, 16 patients were prospectively randomized to receive rituximab with cyclophosphamide, vincristine and prednisone (R-CVP) or double dose rituximab (DDR). Retreatment with standard dose rituximab demonstrated responses similar to initial rituximab treatment in 15 of 20 patients. Neither of the two more intensive regimens (R-CVP, DDR) induced responses in any patien... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2764051 Fri, 24 Jul 2009 23:00:00 +0100 2764051 http://www.medworm.com/index.php?rid=2739201&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21509 RANKL is a key mediator of osteoclast differentiation, activation, and survival. Preclinical data suggest that aberrant production and activation of osteoclasts may influence proliferation of multiple myeloma (MM) cells in the bone marrow. Reports have also shown that inhibiting RANKL may have a direct effect on RANK-expressing myeloma cells and a therapeutic role in treating the disease. In mouse myeloma models, inhibition of RANKL led to reduced serum paraprotein levels and tumor burden. Based on this hypothesis, this proof-of-concept, single-arm study investigated whether RANKL inhibition with denosumab could reduce serum M-protein levels in relapsed or plateau-phase myeloma subjects. All subjects received denosumab monthly, with loading doses on days 8 and 15 of month one, until diseas... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2739201 Fri, 24 Jul 2009 23:00:00 +0100 2739201 http://www.medworm.com/index.php?rid=2739200&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21511 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2739200 Fri, 24 Jul 2009 23:00:00 +0100 2739200 http://www.medworm.com/index.php?rid=2728235&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21506 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2728235 Fri, 24 Jul 2009 23:00:00 +0100 2728235 http://www.medworm.com/index.php?rid=2623464&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21476 This report compares the relative rates and risk factors associated with stroke in adults versus children with sickle cell disease (SCD) in the United States over the last decade. We identified incident strokes in patients with SCD using ICD-9 codes for acute stroke and SCD and the California Patient Discharge Databases. We estimated SCD prevalence by using the incidence of SCD at birth with adjustment for early mortality from SCD. We identified 255 acute strokes (70 primary hemorrhagic and 185 ischemic) among 69,586 hospitalizations for SCD-related complications from 1998 to 2007. The rate of stroke in children [ (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2623464 Tue, 21 Jul 2009 23:00:00 +0100 2623464 http://www.medworm.com/index.php?rid=2607755&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21475 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2607755 Thu, 16 Jul 2009 23:00:00 +0100 2607755 http://www.medworm.com/index.php?rid=2739203&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21498 No abstract. (Source: American Journal of Hematology) American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2739203 Wed, 15 Jul 2009 23:00:00 +0100 2739203 http://www.medworm.com/index.php?rid=2739202&cid=s_33582_19_f&fid=33582&url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fajh.21501 Splenectomy is a common therapy for adults with chronic idiopathic thrombocytopenic purpura (ITP). Thisstudy was designed to estimate both the short-term surgical non-response rate and the long-term relapse rate after laparoscopic splenectomy. A systematic review was conducted of articles published between January 1, 1991 and January 1, 2008. Selection criteria included: chronic ITP, study enrollment in 1990 or later, [ge]12 months of follow-up, [ge]15 patients with ITP, [ge]75% of patients at least 14 years of age, not HIV positive, not undergoing a second splenectomy, and type of performed splenectomy clearly reported. Data were pooled across studies to estimate rates. We identified 170 articles, of which 23 met our inclusion criteria (all observational studies). These studies represent ... American Journal of Hematology journals http://www.medworm.com/rss/comments.php?id=2739202 Wed, 15 Jul 2009 23:00:00 +0100 2739202